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BACKGROUND: Stem cell-based therapy may represent the first realistic option for tissue repairing and regeneration. Mesenchymal stem 
cells (MSCs) are proved to be involved in the regeneration 
of many tissues which are subjected to different types of 
injury. Cyclosporine (CsA) in spite of its use as immune 
suppressive drug during kidney transplantation, it was 
considered as important model of nephropathy specially, 
during long-term administration.
METHODS: Isolation and preparation of MSCs using 
Dulbecco's modified Eagle's medium (DMEM), in vitro 
differentiation through adipogenesis chondrogenesis 
and osteogenesis was confirmed by using Alizarin Red S 
stain, Oil Red O stain and Alcian Blue stain, respectively, 
characterization using flow cytometry technique to detect 
cluster of differentiation (CD)34, CD44 and CD105 surface 
markers and homing of MSCs using polymerase chain 
reaction (PCR) Sry gene assay, were executed. Serum levels 
of vascular endothelial growth factor (VEGF), endothelin-1 
(ET-1) and endothelial nitric oxide synthase (eNOS) were 
quantified using enzyme-linked immunosorbent assay 
(ELISA) kits based on the principle of double-antibody 
sandwich technique. The structural organization of kidney 
tissue was examined using histological procedures. 
RESULTS: Single intravenous dose of MSCs is capable 
to boost kidney repairment process as indicated by the 
significant decrease in serum ET-1 level paralleled by 
significant increase in VEGF and eNOS. Moreover, 
histological findings revealed the improvement of focal 
hemorrhage in between the degenerated tubules, congestion 
in the cortical blood vessels, vacuolization in the endothelial 
cells lining the glomerular tufts and focal perivascular 
inflammatory cells aggregation. 
CONCLUSION: This study demonstrated the favorable 
influence of MSCs in repressing cyclosporine-induced 
nephropathy in rats. This could be achieved through 
angiogenic and anti-arteriolopathic mechanisms. 
KEywORDS: angiogenesis, cyclosporine, endothelin-1, 
MSCs, nephropathy
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Abstract
Introduction
Induction of renal arteriolopathy by cyclosporine (CsA) 
nephrotoxicity may be augmented by the action of vasoactive 
molecules mainly vasoconstrictors. Nitric oxide (NO) plays 
an important role in renal physiology and pathophysiology.
(1) NO was first  found in 1987 to be typical with endothelial 
derived relaxing factor (EDRF) (2), and this was followed by 
a quick package of information identifying the significance 
of NO not only in vascular system and hemodynamics but 
also in nervous and immune defense systems (3).
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 Endothelin-1 (ET-1) is the most powerful mammalian 
vasoconstrictor. In 1990, the document came out to link 
ET-1 with acute CsA nephrotoxicity. CsA has been found to 
stimulate ET-1 production in cultured renal epithelial cells 
and the renal ET receptors have been shown to be amplified 
in rats with CsA-induced nephrotoxicity.(4) Vascular 
endothelial growth factor (VEGF) is considered as signal 
protein of the formation of new blood vessels (5), it has 
main role on acute and chronic renal diseases (6,7). In late 
stages of renal disease, down regulation of VEGF expression 
and increasing of capillaries injury were observed in CsA-
mediated nephrotoxicity.
 Angiotensin II is a well-known growth factor 
stimulating the activity of fibroblast, leading to deposition 
of extracellular matrix, and the scarring of tissue. 
Administration of angiotensin II in rats for a long period 
induces tubulointerstitial damage. This damage is also 
observed after chronic CsA administration.(8) The 
blockade of renin angiotensin system (RAS) in chronic CsA 
nephropathy by angiotensin converting enzyme inhibitor 
(ACEI) decreases blood pressure, potentiates vasodilation 
of afferent arteriole, and ameliorates interstitial fibrosis.
(9) Mesenchymal stem cells (MSCs) are proved to be 
involved in the regeneration of many tissues subjected to 
different types of injury.(10) Since, bone marrow derived 
mesenchymal stem cells (BM-MSCs) and adipose tissue 
derived mesenchymal stem cells (AD-MSCs) have been 
evaluated in a chronic renal damage model with promising 
results. AD-MSCs and BM-MSCs sources of MSCs were 
used to treat the nephrotoxic effects of CsA in this study.
 Herein, the focus of our study is to explore the 
mechanisms behind the therapeutic efficacy of BM-MSCs 
and AD-MSCs in mitigating nephrotoxicity induced by CsA 
in rats.  In addition, the study was extended to elucidate 
the role of stem cell versus angiotensin converting enzyme 
inhibitor in kidney repair. Moreover, introducing awareness 
for the nephrologists for renal dysfunction due to CsA 
administration.
Methods
Isolation and preparation of MSCs were established 
according to Alhadlaq and Mao (11) and Tomiyama, et al., 
(12) using Dulbecco's modified Eagle's medium (DMEM) 
(GIBCO/BRL, New York, USA), supplemented with 10% 
foetal bovine serum (GIBCO/BRL). In addition, to confirm 
the mesenchymal nature of the isolated cells, in vitro 
differentiation of bone marrow and adipose derived cells 
including adipogenesis assay (13), chondrogenesis assay 
(14) and osteogenesis assay (15) was done. Moreover, flow 
cytometry (Beckman Coulter Elite XL, California, USA) 
was used to detect cluster of differentiation (CD)34, CD44 
and CD105 surface markers in order to confirm whether the 
isolated BM-MSCs and AD-MSCs maintain their phenotype 
after expansion in culture.(16) Moreover, isolated MSCs 
from normal female rats were inoculated in male rats to 
confirm their renal homing using polymerase chain reaction 
(PCR) Sry gene assay.(17)
 
Animals
Adult female Wistar rats weighed 130-150 gram, were used 
in this study. Rats were housed in a controlled area where 
temperature (25±1°C) and humidity (55%) were set with 
free access of food and water. Guidelines of the Ethical 
Committee of the National Research Centre, Egypt (IRB 
approval number 14 036) were followed, which conform 
to the recommendations of the National Institutes of Health 
guide for the care and use of Laboratory animals (NIH 
Publications No. 8023, revised 1978). 
 Nephropathy was induced in rats by a daily 
subcutaneous injection of cyclosporine (Novartis Pharma, 
Basel, Switzerland) at the dose of 15 mg/kg dissolved in 
olive oil for 28 days.(18) Dose of angiotensin converting 
enzyme inhibitors (ACEI); 40 mg/L Lisinopril (Zestril, 
AstraZeneca, Cambridge, UK) in drinking water, was 
chosen based on of previously published study.(19)
Experimental Set-up
This study included 64 adult female rats, divided into 
five groups, which are control group (8 rats), healthy rats 
received 1 mL of olive oil subcutaneously for 28 days; 
CsA group (8 rats), healthy rats received 15 mg/kg of 
cyclosporin A subcutaneously for 28 days; BM-MSCs-
treated group (16 rats), nephropathic rats infused with a 
single dose of undifferentiated BM-MSCs (3×106 cells) 
intravenously (20); AD-MSCs-treated group (16 rats), 
nephropathic rats infused with a single dose of AD-MSCs 
(3×106 cells) intravenously (21); ACEI-treated group (16 
rats), nephropathic rats received Lisinopril (40 mg/L) in 
drinking water for one month (8 rats) and two months (8 
rats). After deeply anaesthetized using diethyl ether, the 
rats in the control group as well as in the CsA group were 
sacrificed after treatment. While, all treated groups divided 
into two subgroups equally and were sacrificed after one 
and two months post treatment.
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Biochemical Analyses
Serum creatinine and urea were estimated by auto analyzer 
A15 (Biosystem, Barcelona, Spain). Serum VEGF, ET-1 
and endothelial nitric oxide synthase (eNOS) levels were 
determined according to the manufacturer's instructions 
by using enzyme-linked immunosorbent assay (ELISA) 
kits based on the principle of double-antibody sandwich 
technique, the optical density (OD) was measured under 
450 nm wavelength within 10 min after adding the stop 
solution. The standard curve linear regression equation was 
calculated, and then OD values of the samples were applied 
on the regression equation to calculate the corresponding 
concentration of samples. Kits were purchased from Glory 
Science Co. (Del Rio, Texas, USA).
Histopathological Investigation 
After fixation of kidney samples in 10% formalin saline for 
twenty-four hours, paraffin wax tissue blocks were prepared 
for sectioning at 4 microns by microtome. The obtained 
tissue sections were collected on glass slides, deparaffinized 
and stained by hematoxylin and eosin (H&E) stains for 
histopathological examination.(22)
Statistical Analysis
All results were expressed as Mean±standard deviation 
(SD). Data were analyzed by one way analysis of variance 
(ANOVA) using the Statistical Package for the Social 
Sciences (SPSS) program, version 17 followed by least 
significant difference (LSD) to compare significance 
between groups. Difference was considered significant 
when p-value< 0.05.
Our previous data have shown that, the adherent cells from 
bone marrow and adipose tissue generated many colonies 
and displayed a heterogeneous morphology with elongated 
spindle like shape. Moreover, differentiation of BM-MSCs 
and AD-MSCs through adipogenesis chondrogenesis and 
osteogenesis was confirmed by using Alizarin Red S stain, 
Oil Red O stain and Alcian Blue stain, respectively.(23,24) 
Flow cytometry findings showed that BM-MSCs were 
positive for CD44 (77.1±18.1) and CD105 (78.7±16.3) 
and negative for CD34 (1.62±0.43). Also, AD-MSCs 
characterization using flow cytometry showed CD44 
positive (81.2±19.6) and CD105 positive (74.3±16.9), but 
CD34 negative (3.05±0.71). Where, number of samples 
equal three from each type of MSCs.(17)
Results
 Also, our previous study revealed that the treatment 
with BM-MSCs, AD-MSCs and ACEI after one and two 
months evoked significant (p˂0.05) decline in serum 
creatinine and urea levels paralleled by significant (p˂0.05) 
elevation in glomerular filtration rate (GFR) value in 
comparison with CsA group.(17) 
Biochemical Markers
Table 1 displayed the levels of serum ET-1, VEGF and 
eNOS in the different studied groups. CsA group showed 
significant (p˂0.05) rise of serum ET-1 along with significant 
(p˂0.05) drop of serum VEGF and eNOS levels compare 
to the control group. However, BM-MSCs, AD-MSCs and 
ACEI-treated groups showed significant (p˂0.05) changes 
in serum ET-1, VEGF and eNOS levels as compared to CsA 
group. 
 By comparing the data of BM-MSCs, AD-MSCs and 
ACEI-treated groups after 2 months with those treated after 
1 month, it show that there was significant (p˂0.05) increase 
in serum eNOS level after 2 months of treatment. Meanwhile, 
there  was  significant  (p˂0.05)  decline  in serum  eNOS 
leve l of  AD-MSCs  treated  group  after 1 month versus that 
treated with BM-MSCs after 1 month. Treatment with ACEI 
for 2 months led to significant (p˂0.05) depletion in serum 
VEGF level versus the groups of rats  treated  either  with 
ACEI  for  1  month  or  BM-MSCs for 2 months. 
Histopathological Findings
Control group showed normal histological organization 
of the glomeruli and tubules at the cortex (Figure 1A). 
CsA group revealed focal hemorrhage in between the 
degenerated tubules at the cortex associated with congestion 
in the cortical blood vessels and perivascular inflammatory 
cells infiltration (Figure 1B). BM-MSCs-treated group 
(after one month) revealed focal hemorrhage in between 
the degenerated tubules at the corticomedullary portion 
associated with congestion in the cortical blood vessels, 
swelling and vacuolization in the endothelial cells lining the 
glomerular tufts (Figure 1C). After 2 months of treatment 
with BM-MSCs, congestion in the cortical blood vessels 
was observed (Figure 1D). AD-MSCs-treated group (after 
one month) revealed mild congestion in the cortical portion 
(Figure 1E). There was no histopathological alteration seen 
after two months of treatment with AD-MSCs (Figure 1F). 
Treatment with ACEI led to focal hemorrhage and hemolysis 
between the degenerated tubules in corticomedullary 
portion after one month (Figure 1G) and mild congestion in 
the cortical blood vessels associated with focal perivascular 
inflammatory cells aggregation after 2 months (Figure 1H).
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1st Month 2nd Month 1st Month 2nd Month 1st Month 2nd Month
Endothelin-1 (ng/L) 10.3±1.0 16.02±2.1a 13.53±1.03b 13.2±0.55b 13.1±1.8b 11.5±0.85b 14.6±2.4 13.6±3.3b
VEGF (ng/L) 516±18.3 239.7±11.7a 305.5±9.99b 313.3±16.6b 298.6±12b 316.6±6.8b 309.6±9.5b 293±19.1ef
eNOS (U/mL) 5.9±0.56 3.2±0.52a 4.5±0.41b 5.2±0.36bc 3.9±0.22bc 5.1±0.23bd 4.3±0.35b 4.8±0.3be
Parameters Control group CsA group
BM-MSC- treated group AD-MSC- treated group ACEI- treated group
Table 1.  Serum levels of ET-1, VEGF and eNOS in the control group, CsA group and the treated groups with BM-MSCs, AD-
MSCs and ACEI after one and two months.
a: significant change at p< 0.05 in comparison with the control group; b: significant change at p< 0.05 in comparison with the CsA 
group; c: significant change at p< 0.05 in comparison with BM-MSCs-treated group after one month; d: significant change at p< 0.05 in 
comparison with AD-MSCs-treated group after one month; e: significant change at p< 0.05 in comparison with ACEI-treated group after 
one month; f: significant change at p< 0.05 in comparison with BM-MSCs-treated group after two months.
Discussion
The positive effects of MSC in animal models of CKD 
were mentioned lastly, as indicated by the depletion of 
plasma creatinine levels (25), improvement of proteinuria 
(26), renal fibrosis (27), glomerulosclerosis (28), and renal 
filtration (29). Unfortunately, the exact mechanisms behind 
these reparative processes are presently unknown.
 The long-term administration of CsA as 
immunosupressor agent for patients with renal and heart 
transplantation promote endothelial cell damage through 
high level of Von Willebrand factor, pselectin, thrombin 
complexes (30), and suppress basal and stimulated NO 
generation resulted in severe vascular disease.(31) CsA 
could also induce imbalance in the rate of vasodilator to 
vasoconstrictor in favor of vasoconstriction leading to low-
grade ischemic injury, which is likely associated with CsA 
nephrotoxicity.(32) Therefore, the decrease in GFR after 
CsA injection suggests the involvement of vasoconstriction 
in the mechanism of its nephrotoxicity. 
 The simultaneous significant elevation in serum 
creatinine and urea levels in CsA-group versus the control 
group confirms the later suggestion. CsA has been found 
to increase ET-1 production from renal epithelial cell 
culture and the renal ET receptors showed overexpression 
in rats with nephrotoxicity induced by CsA.(4) The excess 
production of thromboxane due to CsA is linked with the 
activated infiltrating platelets and macrophage in kidney 
tissue, amplification of kidney lipid peroxidation, and 
generation of ROS with consequent endothelial injury.(33) 
This supports the study by another study which proved that 
CsA-induced chronic ischemia is associated with ROS and 
lipid peroxidation.(34) In addition, the significant attenuation 
of CsA nephropathy after antioxidants supplementation 
confirms this idea.(35) The restricted expression of VEGF 
in glomerular and some tubular cells of adult kidneys 
confirms its implication in maintaining permeability and 
integrity of the glomerulus's capillaries. The results of this 
study showed that serum level of VEGF is significantly 
reduced in CsA group relative to the control group. This 
reduction emphasizes the involvement of VEGF in CsA-
mediated nephrotoxicity. Surprisingly, the mean level of 
such marker is significantly elevated in serum of rats after 
treatment with both AD-MSCs and BM-MSCs in a time 
dependent manner. This elevation may suggest an induction 
of a vascular protection-related pathway by the inoculated 
MSC in this study. The essentialities of VEGF in endothelial 
and vascular system development and in glomerulogenesis 
confirm our later suggestion. 
 More evidence in the implication of MSCs in the 
promotion of angiogenesis is by acting as pericyte-like cells 
to support the new vasculature and/or secreting molecules 
strongly associated with the angiogenetic process including 
VEGF, insulin-like growth factor 1 (IGF-1), hepatocyte 
growth factor (HGF), placental growth factor (PIGF), 
monocyte chemoattractant protein-1 (MCP-1), platelet-
derived growth factor (PDGF) and fibroblast growth 
factor 2 (FGF-2).(36,37,38) A somewhat similar kidneys 
repair mechanism may be involved in MSCs-treated rats, 
in our study. This mechanism agrees with the protective 
role of VEGF against glomerular injury.(29,39) Moreover, 
the results of Miyamoto, et al., showed that VEGF 
expression is inversely correlated with the development of 
glomerulosclerosis in progressive renal diseases necessitate 
the implication of the latter mechanism.(40)
 CsA-induced acute renal injury, is believed to be 
associated with abnormal expression of nitric oxide synthase 
(NOS).(41) Previous studies cited that the changes in eNOS 
and inducible nitric oxide synthase (iNOS) expression in 
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Figure 1. Histopathological findings of study 
subjects. A: no histopathological change and 
the normal histological organization of the 
glomeruli and tubules at the cortex are seen in 
the photomicrograph of kidney tissue section of 
rat in the control group; B: focal hemorrhage is 
detected in between the degenerated tubules at the 
cortex associated with congestion in the cortical 
blood vessels and perivascular inflammatory 
cells infiltration are noticed in photomicrograph 
of kidney tissue section of rat in CsA group; C: 
focal hemorrhage in between the degenerated 
tubules at the corticomedullary portion associated 
with congestion in the cortical blood vessels 
and swelling as well as vacuolization in the 
endothelial cells lining the glomerular tufts are 
seen in photomicrograph of kidney tissue section 
of rat in the BM-MSCs-treated group for one 
month; D: congestion is noticed in the cortical 
blood vessels in photomicrograph of kidney tissue 
section of rat in BM-MSCs-treated group for 
two months; E: mild congestion in the cortical 
portion is detected in photomicrograph of kidney 
tissue section of rat in AD-MSCs-treated group 
for one month; F: no histopathological alteration 
is seen in photomicrograph of kidney tissue 
section of rat in AD-MSCs-treated group for two 
months; G: The corticomedullary portion showing 
focal hemorrhage and hemolysis between the 
degenerated tubules in photomicrograph of 
kidney tissue section of rat in ACEI-treated group 
for one month; H: mild congestion in the cortical 
blood vessels associated with focal perivascular 
inflammatory cells aggregation are detected in 
photomicrograph of kidney tissue section of rat in 
ACEI group for two months. White bar: 100 µm.
the diseased kidneys cause a sustained afferent arteriolar 
vasoconstriction.(41-43) 
 VEGF has been found to induce endothelial NO 
formation and this mechanism has a favorable impact in 
maintaining endothelial cell viability (44), inhibition of 
vascular inflammation and suppression of the vascular 
smooth muscle cell activation resulting in preservation of 
vascular integrity.(5) Meanwhile in this study, not only the 
serum levels of VEGF but also NOS levels are significantly 
increased in-group injected with BM-MSCs or AD-MSCs, 
compared with those in CsA group. These increments 
might be one of the mechanisms by which these cells can 
participate to ameliorate CsA-induced nephrotoxicity. 
 Noteworthy, the serum level of NOS in rats treated 
with MSCs is negatively correlated with transforming 
growth factor (TGF)-β level in the same animal groups 
(data not shown). NOS inhibition in rats via L-arginine 
analogue leads to increased afferent arterioles construction, 
which is associated with local activation of RAS and 
overexpression of TGF-β in the kidneys.(45) In addition, A 
progressive nephropathy induced by CsA can be modulated 
by NO stimulation with consequent downregulation of 
TGF-β expression.(46) Since TGF-β is a key player in 
the development of renal fibrosis by direct stimulation of 
extracellular matrix (ECM) components and inhibition of 
collagenase production, will ultimately resulting in renal 
scarring (47), in which one can state that the stimulation 
of NOS to the suggested mechanisms of kidney repairs by 
MSCs in the present study.
 ET-1 can also disrupt renal architecture due to 
its impact on ECM accumulation and tubulointerstitial 
fibrosis. However, both vasoconstriction and afferent 
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arteriolopathy have been shown to be normalized paralleled 
by improvement of the histological feature of kidney in 
the groups treated with MSCs particularly AD-MSCs. 
The normalization of both vasoconstriction and afferent 
arteriolopathy detected in ACEI, BM-MSCs and AD-MSCs-
treated groups confirm this suggested mechanism. Also, the 
disruption of renal architecture and the tubulointerstitial 
inflammation observed in CsA model and the disappearance 
of most of these abnormalities after treatment with MSCs 
add more light to the previous proposed mechanisms.
 Another important mechanism on the line of impairing 
nephrotoxicity induced by CsA involves activation of RAS 
via hemodynamic pathway. This is mediated by inhibition 
of angiotensin II which is a causative factor of endothelial 
cell apoptosis in vitro.(48) This is because of the treatment 
of rats with ACEI, Lisinopril causes an elevation in the 
level of eNOS but decreases ET-1 compared with CsA-
challenged rats, with a simultaneous improvement in kidney 
architecture. The vasoconstricting activity which is partially 
related to the activation of RAS, ET-1 and imbalance 
in prostaglandins and thromboxane (49), confirms the 
possibility of a mechanism based on RAS inhibition to be 
involved in kidney repair after treatment with Lisinopril. 
Conclusion
this study demonstrated that cell therapy elicited 
angiogenesis and anti-arteriolopathic effects in a rat model 
of nephropathy induced by CsA. The increment of eNOS and 
VEGF may be one of the mechanisms underlying the reno-
protective properties of mesenchymal stem cell. Moreover, 
our findings shed more light on the potential rationale for 
the clinical application of stem cell-based therapy in kidney 
diseases.
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